Journal of Cancer Clinical Trials

About the Journal

NCBI NLM ID: 101683470

Cancer is a group of diseases results in abnormal cell growth with the ability to invade or spread to other parts of the body. Not all tumors are cancerous; benign tumors do not spread to other parts of the body. The symptoms of the disease includes new lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. Cancer Clinical trials are research studies carried out on human volunteers to test the efficacy of a new drug or procedures. These studies are mainly conducted to prevent, detect or treat cancer.
 

Journal of Cancer Clinical Trials is a Scholarly Open Access journal that deals with the study of cancer research and publishes original research articles, reviews, short reports, mini reviews, and letters to the editor. The Journal consider articles on all types of cancer clinical trials, including cancer clinical trials, including breast cancer, lung cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, blood cancer, colon cancer, cervical cancer, skin cancer, oesophagal cancer, kidney cancer, brain cancer, metastatic breast cancer, osteosarcoma, oncology, cancer clinical trials and ethical issues, glioblastoma, cancer clinical trials management, etc.

Journal of Cancer Clinical Trial: Open access is using Editor Tracking System to maintain the quality of the online manuscript submission and peer review process. Review processing is performed by the editorial board members of the Journal or by outside experts. At least two independent reviewers approval followed by editor's approval is mandatory for acceptance of any citable manuscript.

Hilaris SRL is a leading Open Access publisher that publishes more than 700 leading-edge peer reviewed Open Access Journals and organizes over 1000 International Conferences globally with the support of nearly 1000 International Societies. Hilaris SRLjournals cater to over 3 million readers with the support of 50000 eminent personalities as editorial board members.

Submit manuscript at https://www.scholarscentral.org/submissions/cancer-clinical-trials.html or send as an e-mail attachment to the Editorial Office at submissions@hilarisjournal.com

Rapid Publication Service

Hilaris Publishing is offering wide range of opportunities, options and services for the prospective authors to publish their scholarly contributions.

The journal caters to the demands of the fast publication without compromising on the editorial quality including manuscript peer-review. This flexibility is being provided to ensure earliest author credibility to their respective contributions and this will also ensure timely dissemination of research outcomes for efficient integration, effective translation and reduced redundancy.

Authors have the option to choose between the standard open access publication service which takes its own course of time for complete publication process or can opt for rapid publication service wherein the article is published at the earliest date (Includes multiple subject experts commissioning for securing earliest peer-review comments). The authors can avail this flexibility based on the personal preference, funding agency guidelines or Institutional or organizational requirements.

Regardless of the option, all manuscripts undergo thorough peer-review process, editorial assessment and production process.

Fast Editorial Execution and Review Process (FEE-Review Process)

Authors who are willing to publish their articles under this mode can make a pre-payment of $99 towards express peer-review and editorial decision. First editorial decision in 3 days and final decision with review comments in 5 days from the date of submission. Galley proof generation will be done in next 2 days from acceptance or maximum 5 days (For manuscripts notified for revision by external reviewer).

Manuscripts accepted for publication will be charged regular APC.

Authors retain the copyright of their publication and the final version of the article will be published in both HTML and PDF formats as well as XML formats for transmitting to indexing databases. The editorial team of the Journal will ensure adherence to scientific publication guidelines.

Recent Articles

• 

  Lung Cancer Immunotherapy

  Bruce W Robinson*

  Editorial

• 

  Ischemic Cardiovascular Occasions and Postoperative Profound Vein Apoplexy

  Grechanyk Olena*

  Short Communication

• 

  Autologous Bone Marrow Transplantation for the Treatment of Leukemias

  Ramin Oftadeh*

  Short Communication

• 

  HRT for Menopausal Symptoms are Estrogens and Progestoge

  Lobo A. Roger*

  Commentary

• 

  Multiple Primary Lung Cancer

  Bruce F Sabath*

  Commentary

• 

  Chemotherapy for Acute Lymphocytic Leukemia (ALL)

  Baron Ronson

  Commentary